2025 Industry Supported Session

Lunch 'n Learn 2: Advances in Myasthenia Gravis: Emerging Biological Therapies and Clinical Frontiers

Monday, June 9, 2025 - 12:00 PM – 1:30 PM Eastern
Rogers Centre Ottawa, Level 2, Room 207
Faculty: Carolina Barnett-Tapia • Hans Katzberg

Description:
The past decade has been transformative for the treatment of myasthenia gravis. In this symposium, we take stock of our current understanding of the disease and survey the current treatment landscape, with a focus on the evolving role of FcRn inhibitors and their place in therapy. We will explore promising developments and emerging approaches such as complement-targeted and CAR-T cell therapies.

Join us for an exciting session with an updated take on myasthenia gravis and its present – and future – treatment.

Learning Objectives:
- Discuss the mechanisms and clinical outcomes used to evaluate emerging biologic therapies in myasthenia gravis
- Describe novel biologic strategies beyond FcRn inhibition, including complement-targeted and CAR-T cell therapies
- Assess the clinical application and evolving role of FcRn inhibitors in the treatment of myasthenia gravis

Audience: Adult Neurologist, Resident, Fellow, Nurses with interest in topic
Learning Level: Basic (Resident, New Information), Intermediate (Practicing Physician)
Learning Format: Seminar
CanMEDs Roles: Medical Expert , Scholar

Time	Presentation Title	Name of Speaker
12:00 PM ET	Welcome, Disclosures and Polling Set Up	Carolina Barnett-Tapia
12:10 PM ET	Current landscape, mechanisms of action, and outcomes	Carolina Barnett-Tapia
12:30 PM ET	Novel therapies (C5 inhibition, CAR-T)	Hans Katzberg
12:50 PM ET	Place of FcRn inhibition in current and future therapy	Hans Katzberg
1:10 PM ET	Q&A	Carolina Barnett-Tapia, Hans Katzberg
1:25 PM ET	Wrap up & Specific Course Evaluation	

This program was developed and planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.